# Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer

> **NCT01987232** · PHASE1,PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 32 (actual)

## Conditions studied

- Extensive-Stage Small-Cell Lung Cancer

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Carboplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT01987232
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11-05
- **Primary completion:** 2016-08
- **Final completion:** 2017-05-04
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01987232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01987232, "Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01987232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*